Floatz logo

Romidepsin

Pancreatic Polypeptide Tumor

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Pancreatic Polypeptide Tumor cohort.

Asset / SponsorPhaseRating
Temsirolimus
University of Southern California
Phase 2B
Everolimus
Emory University
Phase 2B
Regorafenib
University of Southern California
Phase 2B
Gefetinib
National Cancer Institute (NCI)
Phase 2B
Capecitabine
ECOG-ACRIN Cancer Research Group
Phase 2B

View all 15 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →